Weekly Intravenous and Intraperitoneal Paclitaxel Combined with S-1 for Malignant Ascites due to Advanced Gastric Cancer

Kitayama, Joji; Ishigami, Hironori; Kaisaki, Shoichi; Hidemura, Akio; Kato, Masahiro; Otani, Kensuke; Kamei, Takao; Soma, Daisuke; Miyato, Hideyo; Yamashita, Hiroharu; Nagawa, Hirokazu

doi:10.1159/000290955

Cited by 19 publications

(6 citation statements)

References 37 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the CA125 response showed an excellent correlation with the reduction of ascites and overall survival. We previously showed that the change in ascitic fluid volume was a useful predictor of the outcome of intraperitoneal chemotherapy in gastric cancer patients with peritoneal dissemination [25]. This finding is compatible with the finding that the CA125 response correlates with both reduction of ascites and longer survival.…”

Section: Discussionsupporting

confidence: 82%

Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

et al. 2011

Self Cite

View full text Add to dashboard Cite

Background Serum tumor markers have been shown to correlate with the clinical status of patients with advanced gastric cancer. However, the clinical significance of each tumor marker in patients with peritoneal dissemination has not been fully verified. Methods Four serum markers, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, CA125, and CA72-4, were periodically measured in 102 patients with peritoneal dissemination who received combination intravenous and intraperitoneal chemotherapy. The initial values at diagnosis and after treatment were analyzed in association with clinicopathological factors, response to chemotherapy, and overall survival. Results The sensitivities of CEA, CA19-9, CA125, and CA72-4 for peritoneal metastasis at the initial diagnosis were 19, 36, 46, and 45%, respectively. The CA125 level was significantly correlated with the degree of peritoneal dissemination and the existence of malignant ascites. Patients with ovarian metastasis showed significantly higher levels of CA72-4. The median survival time of patients with an elevated CA125 level was significantly shorter than that of patients with a normal CA125 level (36.7 vs. 16.6 months, p \ 0.001). Multivariate analysis showed that the degree of peritoneal metastasis and an elevated CA125 level were independent prognostic factors. Normalization of the CA125 level after 3 courses of chemotherapy was correlated with reduced ascites and improved survival.Conclusions Serum CA125 and CA72-4 are clinically useful markers in diagnosis, evaluating the efficacy of chemotherapy, and predicting the prognosis of patients with peritoneal dissemination. From an academic point of view, periodic measurements of these markers are warranted in gastric cancer patients with possible peritoneal dissemination.

show abstract

Section: Discussionsupporting

confidence: 82%

Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Median survival time for patients with peritoneal dissemination after surgery is reported to be ~10 months (2). Therefore, various new treatments have been developed for gastric cancer with peritoneal dissemination, including systemic chemotherapy, intraperitoneal chemotherapy and/or hyperthermia, and surgery with extended dissection of lymph nodes or other organs (3)(4)(5)(6)(7). To date, however, the results of these therapies have been unsatisfactory.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of oncolytic reovirus against human gastric cancer with peritoneal metastasis in experimental animal model

Kawaguchi¹

2010

Int J Oncol

View full text Add to dashboard Cite

Abstract. The prognosis of gastric cancer patients with peritoneal dissemination is extremely poor, and the development of an effective treatment is necessary. The aim of this study was to investigate the efficacy of oncolytic reovirus against peritoneal metastasis in human gastric cancer using an experimental animal model. Four human gastric cancer cell lines, including MKN45p, NUGC4, MKN7 and KatoIII, a normal NIH3T3 cell line as a control, and reovirus serotype 3, were used in this study. We evaluated the cytopathic effect of reovirus and the Ras activity in each gastric cancer cell line in vitro. To evaluate oncolytic efficacy in vivo, reovirus (1x10 8 PFU) was administered into the peritoneal cavity of nude mice on days 7, 8 and 9 after inoculation with MKN45p cells. Mean volume of ascites and the total number and weight of the peritoneal tumors were measured after sacrifice. After reovirus infection, cytopathic effect was observed in all four gastric cancer cell lines, but not in the control cells. Ras activation assay showed that Ras activity in all four gastric cancer cell lines increased to a higher level than that in the control cells. In the animal model experiments, mean volume of ascites and the total number and weight of the peritoneal tumors in the reovirus treatment group were significantly lower than those in the control group. In conclusions, intraperitoneal administration of reovirus could be useful as a new modality against peritoneal metastasis in gastric cancer.

show abstract

“…Peritoneal dissemination is common in patients with AGC, approximately 40% of whom exhibit ascites as a clinical symptom. 15,16 To the best of our knowledge, this study is the first to investigate the effectiveness of FTD/TPI in AGC patients with ascites. We found significant differences in OS and DCR between patients with and without ascites.…”

Section: Discussionmentioning

confidence: 97%

Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study

Matsumoto

Yamamura

Ikoma

et al. 2022

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: A trial with trifluridine/tipiracil (FTD/TPI) versus placebo in patients with heavily pretreated metastatic gastric cancer showed that FTD/TPI is effective with manageable toxicity in these patients. However, real-world data on the effects of FTD/TPI in patients with advanced gastric cancer (AGC) are limited. Methods: We retrospectively collected and analyzed the clinicopathological data of patients with AGC who received FTD/TPI monotherapy at our institutions (Kobe City Medical Center General Hospital, Osaka Red Cross Hospital, Himeji Red Cross Hospital, and Kansai Medical University Hospital) between September 2019 and July 2021. Tumor responses were evaluated based on the Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival (OS) and progression-free survival were estimated using the Kaplan-Meier method. Results: A total of 53 patients were included in the study. The median age was 70 (range, 37-85) years; 39 patients (74%) were men; the numbers of patients with Eastern Cooperative Oncology Group performance status scores of 0, 1, and 2 were 10 (19%), 39 (74%), and 4 (8%), respectively; and 27 patients (51%) had diffuse-type histology. A total of 29 patients (56%) had ascites. Prior nivolumab therapy was administered to 49 patients (92%). The response rate and disease control rate (DCR) were 2% and 35%, respectively. The median progression-free survival was 2.4 months, and OS was 5.8 months. Patients with ascites exhibited significantly shorter OS (8.6 vs 4.7 months, P = .0291) than those without ascites, and DCR (54% vs 18%, P = .0055) was significantly worse in patients with ascites. There was no significant difference in the frequency of adverse events of grade 3 or higher between patients with and without ascites. Conclusion: In a real-world setting, FTD/TPI has similar effectiveness as late-line chemotherapy for patients with AGC, including those who previously had received nivolumab.

show abstract

Weekly Intravenous and Intraperitoneal Paclitaxel Combined with S-1 for Malignant Ascites due to Advanced Gastric Cancer

Cited by 19 publications

References 37 publications

Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

Efficacy of oncolytic reovirus against human gastric cancer with peritoneal metastasis in experimental animal model

Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study

Contact Info

Product

Resources

About